DVT and Pregnancy



Pregnancy and the postpartum period are associated with an increased risk of venous thromboembolism (VTE), which complicates 1–2 of 1000–20,000 pregnancies and represents a leading cause of mortality during pregnancy. Strong evidence for the management of pregnancy-related DVT is missing. Different diagnostic tools and treatment regimens are described, but are not adequate especially in resource-poor settings. Nevertheless, proper evaluation of involved risk factors is mandatory in order to reduce the incidence of pregnancy-related DVT and improve outcomes. The clinical awareness of DVT in pregnancy and its timely management help to prevent the dreadful complication, that of pulmonary embolism. Thrombosis and thromboembolism was the leading cause of maternal deaths during 2010–2012 in the UK, occurring in 1.08 in 100,000 maternities. Low-molecular-weight heparins are considered the first-line option in the management of pregnancy-related VTE. Continuation of therapy into the postpartum period is mandatory in proven cases of DVT. Labor management methods of women who are anticoagulated are also essential. Stronger evidences in pregnant women, especially with respect to risk stratification, optimal heparin doses, and correct management of anticoagulation during delivery and postpartum, are essential in managing this condition. A national registry for reporting each case of VTE would add on to improving the quality of health care.


Pulmonary Embolism Deep Vein Thrombosis Maternal Death Unfractionated Heparin Cerebral Venous Thrombosis 


  1. 1.
    Abbasi N, Balayla J, Laporta DP, Kezouh A, Abenhaim HA. Trends, risk factors and mortality among women with venous thromboembolism during labour and delivery: a population-based study of 8 million births. Arch Gynecol Obstet. 2014;289(2):275–84.PubMedCrossRefGoogle Scholar
  2. 2.
    Aburahma AF, Mullins DA. Endovascular caval interruption in pregnant patients with deep vein thrombosis of the lower extremity. J Vasc Surg. 2001;33(2):375–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Ahearn GS, Hadjiliadis MD, Govert JA, Tapson VF. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator. Arch Int Med. 2002;162:1221–7.CrossRefGoogle Scholar
  4. 4.
    Ambruso DR, Leonard BD, Bies RD, Jacobson L, Hathaway WE, Reeve EB. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood. 1982;60:78–83.PubMedGoogle Scholar
  5. 5.
    American College of Obstetricians and Gynecologists. Practice Bulletin No. 137: Gestational diabetes mellitus. Committee on Practice Bulletins—Obstetrics. Obstet Gynecol. 2013;122(2 Pt 1):406–16.Google Scholar
  6. 6.
    Andersen BS, Steffensen FH, Sorensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and puerperium—an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand. 1998;77:170–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Bain E, Wilson A, Tooher R, Gates S, Davis L-J, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Published online 11 Feb 2014. Editorial Group: Cochrane pregnancy and childbirth group.Google Scholar
  8. 8.
    Bansal BC, Gupta RR, Prakash C. Stroke during pregnancy and puerperium in young females below the age of 40 years as a result of cerebral venous/venous sinus thrombosis. Jpn Heart J. 1980;21:171–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and thrombolytic therapy. Chest. 2004;163:627S–44.CrossRefGoogle Scholar
  10. 10.
    Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):844S–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Battinelli EM, Marshall A, Connors JM. The Role of Thrombophilia in Pregnancy. Thrombosis. vol. 2013. 2013. Article ID 516420, 9 pages, http://dx.doi.org/10.1155/2013/516420. Review Article.
  12. 12.
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Brandjes DP, Buller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal–vein thrombosis. Lancet. 1997;349:759–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med. 2002;126:1376–81.PubMedGoogle Scholar
  15. 15.
    Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003;16:153–68.PubMedCrossRefGoogle Scholar
  16. 16.
    Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med. 2000;343:1439–44.PubMedCrossRefGoogle Scholar
  17. 17.
    Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med. 1983;309:340–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Brown MD, Lau J, Nelson RD, Kline JA. Turbidimetric D-dimer test in the diagnosis of pulmonary embolism: a metaanalysis. Clin Chem. 2003;49:1846–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181(5 Pt 1):1113–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol. 1997;73:31–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Cervera R, Piette J, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.PubMedCrossRefGoogle Scholar
  22. 22.
    Chan W-S, Spencer FA, Ginsbergm JS. Anatomic distribution of deep vein thrombosis in pregnancy. Can Med Assoc J. 2010;182(7):657–60.CrossRefGoogle Scholar
  23. 23.
    Christodoulou C, Sangle S, D’Cruz DP. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology (Oxford). 2007;46:907–10.CrossRefGoogle Scholar
  24. 24.
    Chunilal SD, Young E, Johnston MA, et al. The aPTT response of pregnant plasma to unfractionated heparin. Thromb Haemost. 2000;87:92–7.Google Scholar
  25. 25.
    Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol. 2008;199(1):36e1–e5.Google Scholar
  26. 26.
    Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost. 1998;79:1166–70.PubMedGoogle Scholar
  27. 27.
    Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med. 1986;314:1298.PubMedCrossRefGoogle Scholar
  28. 28.
    Condliffe R, Elliot CA, Hughes RJ, Hurdman J, Maclean RM, Sabroe I, van Veen JJ, Kiely DG. Management dilemmas in acute pulmonary embolism. Thorax. 2014;69(2):174–80.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Conti E, Zezza L, Ralli E, Comito C, Sada L, Passerini J, Caserta D, Rubattu S, Autore C, Moscarini M, Volpe M. Pulmonary embolism in pregnancy. J Thromb Thrombolysis. 2014;37(3):251–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost. 1996;76:689–91.PubMedGoogle Scholar
  31. 31.
    Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90(3):1004–8.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Demarmels Biasiutti F, Sulzer I, Stucki B, Wuillemin WA, Furlan M, Lammle B. Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members. Thromb Haemost. 1998;80:167–70.PubMedGoogle Scholar
  33. 33.
    den Heijer M, Kostor T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759–62.CrossRefGoogle Scholar
  34. 34.
    Edward Henry Springel, Thomas Chih Cheng Peng; Thromboembolism in Pregnancy Workup, Medscape CME and education. Reference Apr 30, 2014.Google Scholar
  35. 35.
    Emmi L, Bergamini C, Spinelli A, Liotta F, Marchione T, Caldini A, Fanelli A, De-Cristofaro MT, Dal-Pozzo G. Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. Ann N Y Acad Sci. 1997;823:188–200.PubMedCrossRefGoogle Scholar
  36. 36.
    Ensom MHH, Stephenson MD. Low molecular weight heparins in pregnancy. Pharmacotherapy. 1999;19:1013–25.PubMedCrossRefGoogle Scholar
  37. 37.
    Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982;257:7944–7.PubMedGoogle Scholar
  38. 38.
    Esmon NL, Safa O, Smirnov MD, Esmon CT. Antiphospholipid antibodies and the protein C pathway. J Autoimmun. 2000;15:221–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Forbes KP, Reid JH, Murchison JT. Do preliminary chest X-ray findings define the optimum role of pulmonary scintigraphy in suspected pulmonary embolism? Clin Radiol. 2001;56(5):397–400.PubMedCrossRefGoogle Scholar
  40. 40.
    Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res. 1984;34:557–60.PubMedCrossRefGoogle Scholar
  41. 41.
    Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci. 1985;82:4673–7.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Francalanci I, Comeglio P, Alessandrello Liotta A, Cellai AP, Fedi S, Parretti E, Mecacci F, Mello G, Prisco D, Abbate R. D-dimer plasma levels during normal pregnancy measured by specific ELISA. Int J Clin Lab Res. 1997;27(1):65–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Francis C. Plasminogen activator inhibitor-1 levels and polymorphisms: association with venous thromboembolism. Arch Pathol Lab Med. 2002;126:1401–4.PubMedGoogle Scholar
  44. 44.
    Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost. 1992;67(5):519–20.PubMedGoogle Scholar
  45. 45.
    Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors. J Thromb Thrombolysis. 2004;17:139–43.PubMedCrossRefGoogle Scholar
  46. 46.
    Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259–62.PubMedCrossRefGoogle Scholar
  47. 47.
    Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Greer IA. Inherited thrombophilia and venous thromboembolism. Best Pract Res Clin Obstet Gynaecol. 2003;17:413–25.PubMedCrossRefGoogle Scholar
  49. 49.
    Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thrombo-embolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J. 2000;21(16):1301–36.Google Scholar
  51. 51.
    Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697–706.PubMedCrossRefGoogle Scholar
  52. 52.
    Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S–94.PubMedCrossRefGoogle Scholar
  53. 53.
    Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK. Executive summary: regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010;35(1):102–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Jacob H. Rand, molecular pathogenesis of the antiphospholipid syndrome. Circ Res. 2002;90:29–37.CrossRefGoogle Scholar
  55. 55.
    Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thrombo-embolism in pregnancy. BJOG. 2003;110:139–44.PubMedCrossRefGoogle Scholar
  56. 56.
    Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium—a register-based case-control study. Am J Obstet Gynecol. 2008;198:233.e1–7.CrossRefGoogle Scholar
  57. 57.
    James AH. Venous thromboembolism: mechanisms, treatment, and public awareness. Arterioscler Thromb Vasc Biol. 2009;29:326–31.PubMedCrossRefGoogle Scholar
  58. 58.
    James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311–5.PubMedCrossRefGoogle Scholar
  59. 59.
    James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol. 2005;193:216–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Khan S. Hereditary thrombophilia. Thromb J. 2006;4:15.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie` N, Simon J, Gibbs R, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. DOI: http://dx.doi.org/10.1093/eurheartj/ehu283. First published online: Aug 30 2014.
  62. 62.
    Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol. 2000;182:1089–92.PubMedCrossRefGoogle Scholar
  63. 63.
    Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol. 2002;22:14–20.PubMedCrossRefGoogle Scholar
  64. 64.
    Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77:197.PubMedGoogle Scholar
  65. 65.
    Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost. 1996;76:824.PubMedGoogle Scholar
  66. 66.
    Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG. 2001;108:1134–40.PubMedGoogle Scholar
  67. 67.
    Lijnen HR, Holylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem. 1983;258:3803.PubMedGoogle Scholar
  68. 68.
    Lijnen HR, Soria J, Soria C, et al. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost. 1984;51:108.PubMedGoogle Scholar
  69. 69.
    Lindqvist P, Dahlbäck B, Marsál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol. 1999;94(4):595–9.PubMedGoogle Scholar
  70. 70.
    Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol. 1997;104(2):191–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Makatsaria AD, Bitsadze VO, Dolgushina NV. Use of the low-molecular-weight heparin nadroparin during pregnancy. A review. Curr Med Res Opin. 2003;19:4–12.PubMedCrossRefGoogle Scholar
  72. 72.
    Malcolm JC, Keely EJ, Karovitch AJ, Wells PS. Use of low molecular weight heparin in acute venous thromboembolic events in pregnancy. J Obstet Gynaecol Can. 2002;24:568–71.PubMedGoogle Scholar
  73. 73.
    Marcucci R, Liotta AA, Cellai AP, Rogolino A, Gori AM, Giusti B, Poli D, Fedi S, Abbate R, Prisco D. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med. 2003;115:601–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008;359(19):2025–33.PubMedCrossRefGoogle Scholar
  75. 75.
    Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353–8.PubMedGoogle Scholar
  76. 76.
    McCaulley JA, Pates JA. Postpartum cerebral venous thrombosis. Obstet Gynecol. 2011;118(2 Pt 2):423–5.PubMedCrossRefGoogle Scholar
  77. 77.
    McColl MD, Ellison J, Greer IA, Tait RC, Walker ID. Prevalence of the post thrombotic syndrome in young women with previous venous thromboembolism. Br J Haematol. 2000;108:272–4.PubMedCrossRefGoogle Scholar
  78. 78.
    McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–9.PubMedCrossRefGoogle Scholar
  79. 79.
    McLintock C, Brighton T, Chunilal S, Dekker G. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust N Z J Obstet Gynaecol. 2012;52(1):14–22.PubMedCrossRefGoogle Scholar
  80. 80.
    McRae SJ, Ginsberg JS. Treatment of venous thromboembolism; initial treatment of venous thromboembolism. Circulation. 2004;110:I-3-I-9.Google Scholar
  81. 81.
    Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. Febs J. 2005;272:4858–67.PubMedCrossRefGoogle Scholar
  83. 83.
    Meijers JCM, Tekelenburg WLH, Bouma BN, Rogier BM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696–701.PubMedCrossRefGoogle Scholar
  84. 84.
    Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis [published correction appears in JAMA. 1994;271(24)1908]. JAMA. 1994;271(3):223–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Niemann T, Nicolas G, Roser HW, Müller-Brand J, Bongartz G. Imaging for suspected pulmonary embolism in pregnancy—what about the fetal dose? A comprehensive review of the literature. Insights Imaging. 2010;1(5–6):361–72.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Nijkeuter M, Ginsberg JS, Huisman MV. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. J Thromb Haemost. 2006;4(3):496–500.PubMedCrossRefGoogle Scholar
  87. 87.
    O’Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997;77:825–8.PubMedGoogle Scholar
  88. 88.
    Ohlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost. 1997;78:396–400.PubMedGoogle Scholar
  89. 89.
    Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev. 1994;8(1):37–55.PubMedCrossRefGoogle Scholar
  90. 90.
    Polak JF, Wilkinson DL. Ultrasonographic diagnosis of symptomatic deep venous thrombosis in pregnancy. Am J Obstet Gynecol. 1991;165(3):625–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-Untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.PubMedGoogle Scholar
  93. 93.
    Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140:175–83.PubMedCrossRefGoogle Scholar
  94. 94.
    Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 1999;54:265–71.PubMedCrossRefGoogle Scholar
  95. 95.
    Reiner Alexander P, Siscovick David S, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol. 2001;5:262–87.CrossRefGoogle Scholar
  96. 96.
    Rowan JA, McLintock C, Taylor RS, North RA. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust N Z J Obstet Gynaecol. 2003;43:123–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Sangle SR, D’Cruz DP, Jan W, Karim MY, Khamashta MA, Abbs IC, Hughes GR. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis. 2003;62:999–1002.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Sangle SR, Jan W, Lau IS, Bennett AN, Hughes GRV, D'Cruz DP. Coeliac artery stenosis and antiphospholipid (Hughes) syndrome/antiphospholipid antibodies. Clin Exp Rheumatol. 2006;24:349.PubMedGoogle Scholar
  99. 99.
    Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, et al. Safety of low molecular weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81:668–72.PubMedGoogle Scholar
  100. 100.
    Scarsbrook AF, Evans AL, Owen AR, Gleeson FV. Diagnosis of suspected venous thromboembolic disease in pregnancy. Clin Radiol. 2006;61:1–12.PubMedCrossRefGoogle Scholar
  101. 101.
    Schaefer C, Hannemann D, Meister R, Eléfant E, Paulus W, Vial T. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost. 2006;95(6):949–57.PubMedGoogle Scholar
  102. 102.
    Schmidel DK, Tatro AV, Phelps LG, Tomczak JA, Long GL. Organization of the human protein S genes. Biochemistry. 1990;29:7845–52.PubMedCrossRefGoogle Scholar
  103. 103.
    Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost. 1996;75:607–11.PubMedGoogle Scholar
  104. 104.
    Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, Toh CH. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol. 2003;101(6):1307–11.PubMedGoogle Scholar
  105. 105.
    Simpson EL, Lawrenson RA, Nightingale AL, et al. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG. 2001;108:56–60.PubMedGoogle Scholar
  106. 106.
    Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol. 2004;190:495–501.PubMedCrossRefGoogle Scholar
  107. 107.
    Spritzer CE, Norconk Jr JJ, Sostman HD, Coleman RE. Detection of deep venous thrombosis by magnetic resonance imaging. Chest. 1993;104(1):54–60.PubMedCrossRefGoogle Scholar
  108. 108.
    Sultan AA, Tata LJ, West J, Fiaschi L, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood. 2013;121(19):3953–61.PubMedCrossRefGoogle Scholar
  109. 109.
    Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106–12.PubMedCrossRefGoogle Scholar
  110. 110.
    Tawfik MM, Taman ME, Motawea AA, Abdel-Hady E. Thrombolysis for the management of massive pulmonary embolism in pregnancy. Int J Obstet Anesth. 2013;22(2):149–52.PubMedCrossRefGoogle Scholar
  111. 111.
    te Raa GD, Ribbert LS, Snijder RJ, Biesma DH. Treatment options in massive pulmonary embolism during pregnancy; a case-report and review of literature. Thromb Res. 2009;124(1):1–5.CrossRefGoogle Scholar
  112. 112.
    The Acute Management of Thrombosis and Embolism During Pregnancy and the Puerperium, RCOG Green-top Guideline No. 37b Reviewed 2010.Google Scholar
  113. 113.
    Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk, RCOG Green-top Guideline No. 37a, Nov 2009.Google Scholar
  114. 114.
    Uchikova EH, Ledjev II. Changes in haemostasis in normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;119:185–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Ulander VM, Lehtola A, Kaaja R. Long-term outcome of deep venous thrombosis during pregnancy treated with unfractionated heparin or low molecular weight heparin. Thromb Res. 2003;111:239–42.PubMedCrossRefGoogle Scholar
  116. 116.
    Ulman E, Brady WJ, Perron AD. Electrocardiographic manifestations of pulmonary embolism. Am J Emerg Med. 2001;19(6):514–9.CrossRefGoogle Scholar
  117. 117.
    van Dongen CJJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost. 2005;3:939–42.PubMedCrossRefGoogle Scholar
  118. 118.
    van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2004;(4):CD001100.Google Scholar
  119. 119.
    van Hylckama VA, et al. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678–82.Google Scholar
  120. 120.
    Villa P, Aznar J, Vaya A, Espana F, Ferrando F, Mira Y, Estelles A. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb Haemost. 1999;82:1011–4.PubMedGoogle Scholar
  121. 121.
    Vora S, Ghosh K, Shetty S, Salvi V, Satoskar P. Deep venous thrombosis in the antenatal period in a large cohort of pregnancies from western India. Thromb J. 2007;5:9.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation. 2004;110:744–9.PubMedCrossRefGoogle Scholar
  123. 123.
    Warkentin TE, Greinacher A. Heparin-induced thrombo-cytopenia: recognition, treatment, and prevention; the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):311S–37.PubMedCrossRefGoogle Scholar
  124. 124.
    Wells PS, Anderson DR, Rogers M, et al. Evaluation of d-dimer in the diagnosis of suspected deep venous thromboembolism. N Engl J Med. 2003;349:1227–35.PubMedCrossRefGoogle Scholar
  125. 125.
    Why Mothers Die Kerala – 2006–09 Second Report of Confidential Review of Maternal Deaths, Kerala Maternal Fetal Medicine Committee, Kerala Federation of Obstetrics & Gynaecology Editors: VP Paily, K Ambujam, Betsy Thomas.Google Scholar
  126. 126.
    Wilbur J, Shian B. Diagnosis of deep venous thrombosis and pulmonary embolism. Am Fam Physician. 2012;86(10):913–9.PubMedGoogle Scholar
  127. 127.
    Wong M, Sangle S, Jan W, Hughes GR, D’Cruz DP. Intracerebral arterial stenosis with neurological events associated with antiphospholipid syndrome. Rheumatology (Oxford). 2005;44:948–9.CrossRefGoogle Scholar
  128. 128.
    Yusen RD, Gage BF. Outpatient treatment of acute thrombo- embolic disease. Clin Chest Med. 2003;24:46–61.CrossRefGoogle Scholar
  129. 129.
    Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V mutation in 47 out of 60 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521–4.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyVijayalakshmi Medical CentreKochiIndia

Personalised recommendations